<SEC-DOCUMENT>0000728014-15-000008.txt : 20150218
<SEC-HEADER>0000728014-15-000008.hdr.sgml : 20150216
<ACCEPTANCE-DATETIME>20150217140526
ACCESSION NUMBER: 0000728014-15-000008
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20150217
DATE AS OF CHANGE: 20150217
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: VALEANT PHARMACEUTICALS INTERNATIONAL
CENTRAL INDEX KEY: 0000930184
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330628076
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-44365
FILM NUMBER: 15620841
BUSINESS ADDRESS:
STREET 1: ONE ENTERPRISE
CITY: ALISO VIEJO
STATE: CA
ZIP: 92656
BUSINESS PHONE: 949-461-6000
MAIL ADDRESS:
STREET 1: ONE ENTERPRISE
CITY: ALISO VIEJO
STATE: CA
ZIP: 92656
FORMER COMPANY:
FORMER CONFORMED NAME: ICN PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19941114
FORMER COMPANY:
FORMER CONFORMED NAME: ICN MERGER CORP
DATE OF NAME CHANGE: 19940915
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: RUANE, CUNNIFF & GOLDFARB INC
CENTRAL INDEX KEY: 0000728014
IRS NUMBER: 132628641
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: SC 13G/A
BUSINESS ADDRESS:
STREET 1: 9W 57TH STREET
STREET 2: SUITE 5000
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: 2128325280
MAIL ADDRESS:
STREET 1: 9W 57TH STREET
STREET 2: SUITE 5000
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: RUANE CUNNIFF & CO INC
DATE OF NAME CHANGE: 19970618
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13G/A
<SEQUENCE>1
<FILENAME>vrxa.txt
<TEXT>
<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
Amendment No.: 5
Name of Issuer: Valeant Pharmaceuticals Intl
Title of Class of Securities: Common
CUSIP Number: 91911K102
(Date of Event Which Requires Filing of this Statement)
December 31, 2014
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
/X/ Rule 13d-l(b)
/ / Rule 13d-l(c)
/ / Rule 13d-l(d)
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act
(however, see the Notes).
<PAGE>
CUSIP Number: 91911K102
1. Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Ruane, Cunniff & Goldfarb Inc.
13-2628641
2. Check the Appropriate Box if a Member of a Group
a. / /
b. / /
3. SEC Use Only
4. Citizenship or Place of Organization
Delaware
Number of Shares Beneficially Owned by Each Reporting Person
With:
5. Sole Voting Power:
34,331,973
6. Shared Voting Power:
NONE
7. Sole Dispositive Power:
34,331,973
8. Shared Dispositive Power:
NONE
9. Aggregate Amount Beneficially Owned by Each Reporting
Person:
34,331,973
10. Check Box if the Aggregate Amount in Row (9) Excludes
Certain Shares / /
11. Percent of Class Represented by Amount in Row (9)
10.23%
12. Type of Reporting Person
IA
-2-
<PAGE>
Item 1(a) Name of Issuer:
Valeant Pharmaceuticals Intl
(b) Address of Issuer's Principal Executive Offices:
One Enterprise, Aliso Viejo, CA 92656
Item 2(a) - (c). Name, Principal Business Address, and
Citizenship of Persons Filing:
Ruane, Cunniff & Goldfarb Inc.
9W 57th Street, Ste 5000, New York, NY 10019
Corp. organized under the laws of the State of
Delaware
(d) Title of Class of Securities: Common
(e) CUSIP Number: 91911K102
Item 3. This statement is filed pursuant to Rule
13d-1(b)(1).
/ / Broker or Dealer registered under Section 15 of the
Act;
/x/ Investment Adviser in accordance with
Section 240.13d-1(b)(1)(ii)(E).
Item 4. Ownership.
(a) Amount Beneficially Owned: 34,331,973
(b) Percent of Class: 10.23%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
34,331,973
(ii) Shared power to vote or to direct the vote:
NONE
(iii) shares with sole power to dispose or to
direct the disposition of: 34,331,973
(iv) shares with shared power to dispose or
direct the disposition of: NONE
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact
that as of the date hereof the reporting person has ceased
to be the beneficial owner of more than 5 percent of the
class of securities, check the following / /.
Item 6. Ownership of More than Five Percent on Behalf of
Another Person.
N/A
-3-
<PAGE>
Item 7. Identification and Classification of the Subsidiary
Which Acquired the Security Being Reported on by the Parent
Holding Company or Control Person.
N/A
Item 8. Identification and Classification of Members of the
Group.
N/A
Item 9. Notice of Dissolution of the Group.
N/A
Item 10. Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and are held
in the ordinary course of business and were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction
having that purpose or effect.
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.
Signature
By: /s/ Todd Ruoff February 17, 2015
_______________________________ _________________
Title: Executive Vice-President Date
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>